WNK1 and colorectal cancer: Most notably, the I-C19 treatment reduced the phosphorylation of the WNK1 oncogene (which is overexpressed in colorectal cancer and is mainly involved in the regulation of metabolism) at the levels of 38.6 and 32.6% in the LoVo and SW620 cell lines, respectively [13].